• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.

    1/11/23 6:45:00 AM ET
    $IMGO
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMGO alert in real time by email

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Imago BioSciences, Inc. (NASDAQ:IMGO), at a purchase price of $36.00 per share in cash, without interest and subject to deduction for any required tax withholding. As of the tender offer expiration at one minute after 11:59 p.m., Eastern Time, on January 10, 2023, 31,307,028 shares of common stock of Imago were validly tendered and not withdrawn from the tender offer, representing approximately 89.2% of the total number of Imago's outstanding shares on a fully diluted basis. All such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck expects to promptly pay for such shares.

    Merck intends to complete today the acquisition of Imago through a merger of Merck's wholly owned subsidiary with and into Imago, with Imago being the surviving corporation, in which all shares not tendered into the offer will be cancelled and converted into the right to receive cash equal to the $36.00 offer price per share, without interest and subject to deduction for any required tax withholding. After the completion of the merger, Imago will become a wholly owned subsidiary of Merck and the common stock of Imago will no longer be listed or traded on the Nasdaq Global Market.

    About Merck

    Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.

    Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

    This news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

    Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

    The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2021 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005341/en/

    Get the next $IMGO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMGO
    $MRK

    CompanyDatePrice TargetRatingAnalyst
    Merck & Company Inc.
    $MRK
    5/14/2025$84.00Buy → Neutral
    Citigroup
    Merck & Company Inc.
    $MRK
    4/22/2025$85.00Neutral
    Cantor Fitzgerald
    Merck & Company Inc.
    $MRK
    2/18/2025$128.00 → $105.00Buy → Hold
    Deutsche Bank
    Merck & Company Inc.
    $MRK
    2/10/2025$121.00 → $100.00Buy → Hold
    TD Cowen
    Merck & Company Inc.
    $MRK
    1/8/2025$110.00Buy → Hold
    Truist
    Merck & Company Inc.
    $MRK
    12/20/2024$136.00 → $105.00Outperform → Market Perform
    BMO Capital Markets
    Merck & Company Inc.
    $MRK
    12/10/2024$121.00Buy
    BofA Securities
    Merck & Company Inc.
    $MRK
    12/4/2024$130.00Hold → Buy
    HSBC Securities
    More analyst ratings

    $IMGO
    $MRK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

      Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 10, 2025, at 10:00 a.m. EDT. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science

      6/4/25 6:45:00 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)

      First pivotal Phase 3 trial to show superiority of KEYTRUDA plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that KEYTRUDA® (pembrolizumab) plus Trodelvy® (sacituzumab govitecan-hziy) reduced the risk of disease progression or death by 35% (HR=0.65, p<0.001) versus KEYTRUDA plus chemotherapy for the first-line treatment of patients with PD-L1+ (Combined Positive Score [CPS] ≥10) inoperable (unresectable) locally advanced or metastatic triple-negative breast cancer (TNBC), as determined by an FDA-approved test. KEYTRUDA, when given in combination with

      5/31/25 8:00:00 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merck's Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial

      Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced results from the dose confirmation portion of the Phase 2/3 waveLINE-003 study evaluating zilovertamab vedotin in combination with standard of care rituximab and gemcitabine-oxaliplatin (R-GemOx) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Zilovertamab vedotin is an investigational, potential first-in-class antibody drug conjugate (ADC) that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1). At a pre-planned analysis, zilovertamab vedotin 1.75 mg/kg in combination with R-GemOx achieved a 56.3% objective response rate (ORR) in patients with relapsed or r

      5/30/25 8:00:00 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGO
    $MRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Merck downgraded by Citigroup with a new price target

      Citigroup downgraded Merck from Buy to Neutral and set a new price target of $84.00

      5/14/25 8:57:17 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Merck with a new price target

      Cantor Fitzgerald initiated coverage of Merck with a rating of Neutral and set a new price target of $85.00

      4/22/25 8:01:38 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merck downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded Merck from Buy to Hold and set a new price target of $105.00 from $128.00 previously

      2/18/25 7:11:01 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGO
    $MRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Thulin Inge G bought $250,000 worth of shares (2,833 units at $88.25), increasing direct ownership by 2,833% to 2,933 units (SEC Form 4)

      4 - Merck & Co., Inc. (0000310158) (Issuer)

      2/7/25 4:09:51 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Baker Douglas M Jr bought $1,327,500 worth of shares (15,000 units at $88.50), increasing direct ownership by 1,500% to 16,000 units (SEC Form 4)

      4 - Merck & Co., Inc. (0000310158) (Issuer)

      2/7/25 4:04:52 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGO
    $MRK
    Financials

    Live finance-specific insights

    See more
    • Merck Announces Third-Quarter 2025 Dividend

      Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company's common stock for the third quarter of 2025. Payment will be made on July 8, 2025, to shareholders of record at the close of business on June 16, 2025. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intens

      5/27/25 1:24:00 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merck Announces First-Quarter 2025 Financial Results

      Total Worldwide Sales Were $15.5 Billion, a Decrease of 2% From First Quarter 2024; Excluding the Impact of Foreign Exchange, Sales Grew 1% KEYTRUDA Sales Grew 4% to $7.2 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 6% WINREVAIR Sales Were $280 Million Animal Health Sales Grew 5% to $1.6 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 10% GARDASIL/GARDASIL 9 Sales Declined 41% to $1.3 Billion; Excluding the Impact of Foreign Exchange, Sales Declined 40% GAAP EPS Was $2.01; Non-GAAP EPS Was $2.22 Presented Compelling Data From a Diverse Range of Programs, Including: Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Phase

      4/24/25 6:30:00 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merck to Hold First-Quarter 2025 Sales and Earnings Conference Call April 24

      Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its first-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, April 24. During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Fre

      4/1/25 6:45:00 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGO
    $MRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Merck & Company Inc. (Amendment)

      SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)

      2/13/24 4:55:49 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Imago BioSciences Inc. (Amendment)

      SC 13G/A - Imago BioSciences, Inc. (0001623715) (Subject)

      2/14/23 8:26:45 AM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Merck & Company Inc. (Amendment)

      SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)

      2/9/23 10:54:48 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGO
    $MRK
    SEC Filings

    See more
    • SEC Form SD filed by Merck & Company Inc.

      SD - Merck & Co., Inc. (0000310158) (Filer)

      5/30/25 9:56:39 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merck & Company Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Merck & Co., Inc. (0000310158) (Filer)

      5/29/25 1:46:56 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 13F-HR filed by Merck & Company Inc.

      13F-HR - Merck & Co., Inc. (0000310158) (Filer)

      5/14/25 4:02:08 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGO
    $MRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Warden Kathy J

      4 - Merck & Co., Inc. (0000310158) (Issuer)

      6/3/25 1:45:50 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Thulin Inge G

      4 - Merck & Co., Inc. (0000310158) (Issuer)

      6/3/25 1:25:24 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Seidman Christine E

      4 - Merck & Co., Inc. (0000310158) (Issuer)

      6/3/25 1:22:58 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGO
    $MRK
    Leadership Updates

    Live Leadership Updates

    See more
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components
    • Ashland Board appoints Sanat Chattopadhyay, executive vice president, Merck & Company, as new director effective November 13, 2023

      WILMINGTON, Del., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) has announced the appointment of Sanat Chattopadhyay, executive vice president of Merck & Company (NYSE:MRK) to its Board of Directors. Chattopadhyay will serve on the Board's Environmental, Health, Safety, and Quality and Governance and Nominating Committees, effective November 13, 2023.  Prior to Merck, Chattopadhyay held leadership positions at Wyeth Pharmaceuticals, Aventis, Hoechst Marion Roussel and Hoechst India. As previously announced, Jay V. Ihlenfeld who has served as a director since 2017, and Brendan M. Cummins, who joined the board in 2012 have decided not to stand for re-election at Ashland's Annua

      11/14/23 5:25:00 PM ET
      $ASH
      $MRK
      Specialty Chemicals
      Consumer Discretionary
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer

      Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer Arun Balakumaran M.D., Ph.D, appointed Chief Medical Officer of Replay to support the Company's genomic medicine and engineered NK cell therapy pipelineFormer Chief Medical Officer of allogeneic CAR-T cell company Allogene Therapeutics and seasoned industry immuno-oncology, and cell and gene therapy expert Dr. Balakumaran also appointed CMO of Syena, Replay's engineered NK cell therapy product company pioneering first-in-class engineered T-cell Receptor Natural Killer cell (TCR-NK) therapy San Diego, California and London, UK, May 18, 2023 – Replay, a genome writing company reprogramming biology by writing and deliver

      5/18/23 8:00:00 AM ET
      $ALLO
      $AMGN
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations